0.000
0.00 (0.00%)
AIStockmoo Score
| Value 60% | -5.0 |
| Weak profitability. Thin short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Earnings Trend info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing | NA |
| From our AI technical analysis of the chart. info | NA |
| Trend Strength info | NA |
| Technical Setup info | NA |
| Candle Patterns info | NA |
| Medium-Term Trend info | NA |
| Sentiment 40% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are favourable. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| Only one pillar has a clear reading, so the score is unchanged. | |
| Not in score | |
| Price Volatility info | NA |
| No clear trend across the short, medium and long term. info | |
| No clear signal from support and resistance. info | |
| Final Score | -2.88 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | LumiraDx Limited | - | - |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| LMDWF | - | - | - | - | -2.9 |
| BNR | 140 M | - | - | 1.84 | -0.7 |
| ADVB | - | - | - | 0.280 | -2.3 |
| GH | 20 B | - | - | - | -0.6 |
| MEDP | 18 B | - | 35.20 | 31.23 | 1.2 |
| IDXX | - | - | - | 29.54 | 0.0 |
Select this tab to load the latest available analysis.
|
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cvs Health Corp | 30 Jun 2024 | 5,352,106 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |